Table 2 Previous and concomitant medications (analysis population)

Number of prior DMARDs

  0–3, n (%)

  >3, n (%)

Number of prior anti-TNF agents

  ≥2, n (%)

  <2, n (%)

Type of biologic agent

  Other MOA, n (%)

  Anti-TNF agent

Reason for discontinuation of last biologic

  Intolerance, n (%)

  Primary inefficacy, n (%)^a

  Secondary inefficacy, n (%)^†

  Major improvement + other reasons, n (%)

Abatacept treatment pattern at initiation

  Monotherapy, n (%)

  Combination with MTX (± other DMARDs), n (%)

  Combination with other DMARDs, n (%)

Corticosteroid treatment pattern at abatacept initiation (versus before initiation)^‡

  No corticosteroids, n (%)

  Continuous use of corticosteroids, n (%)

  Stop corticosteroid use, n (%)

  Introduction of corticosteroids, n (%)